Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].

Journal of hepatology·2026
Same author

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).

Alimentary pharmacology & therapeutics·2026
Same author

Correction: Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages.

Frontiers in immunology·2026
Same author

A three-gene resistome signature as a prognostic tool in hepatocellular carcinoma.

Annals of hepatology·2025
Same author

Epidemiology, clinical, molecular features, and prognosis of early-onset biliary tract cancer: A systematic review and meta-analysis.

JHEP reports : innovation in hepatology·2025
Same author

Cholangiocarcinoma 2026: status quo, unmet needs and priorities.

Nature reviews. Gastroenterology & hepatology·2025

Related Experiment Video

Updated: May 25, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Management of HCC.

Carlos Rodríguez de Lope1, Silvia Tremosini, Alejandro Forner

  • 1Barcelona Clinic Liver Cancer Group, Liver Unit, ICMDM, Hospital Clínic, IDIBAPS, University of Barcelona, Spain.

Journal of Hepatology
|February 4, 2012
PubMed
Summary

Hepatocellular carcinoma (HCC) management has improved with staging systems like BCLC. Early-stage HCC offers curative options, while advanced stages utilize treatments like sorafenib for better outcomes.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Experiment Videos

Last Updated: May 25, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Area of Science:

  • Hepatology
  • Oncology
  • Internal Medicine

Background:

  • Hepatocellular carcinoma (HCC) is a prevalent and lethal cancer.
  • Recent advancements have improved HCC management strategies.
  • Understanding tumor biology and staging is crucial for prognosis.

Purpose of the Study:

  • To review current management strategies for Hepatocellular Carcinoma (HCC).
  • To discuss new advances in the field of HCC treatment.
  • To highlight the role of staging systems in guiding treatment decisions.

Main Methods:

  • Review of current literature on Hepatocellular Carcinoma (HCC) management.
  • Analysis of staging systems, including the Barcelona Clinic Liver Cancer (BCLC) system.
  • Discussion of therapeutic approaches based on disease stage.

Main Results:

  • Curative therapies (resection, transplantation, ablation) improve survival in early-stage HCC.
  • Chemoembolization is beneficial for intermediate-stage HCC.
  • Sorafenib, a multikinase inhibitor, is effective for advanced-stage HCC.

Conclusions:

  • Staging systems like BCLC enhance prognostic prediction and treatment selection for HCC.
  • Personalized treatment approaches based on stage significantly impact patient survival.
  • Ongoing research continues to advance HCC treatment options.